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Abstract 
Purpose.  
This work studies the relationship between in-vitro Proton Magnetic Resonance Spectroscopy metabolite 
quantification and water T2 decay. 
Materials and methods.  
An in-vitro correspondence is established between the iron accumulation and the shortening of water T2 relaxation 
times using seven spherical phantoms, 6 of them were doped with an increasing concentration of iron metal 
nanoparticles solution. This is later proposed as a source of error during the LCModel metabolite quantification of 
either absolute concentrations or ratios. 
Results 
The Pearson's correlation coefficient between water T2 values against absolute metabolite concentrations was on 
average [r] = 0.97 and on average [r] = 0.85 for metabolite ratios. 
Conclusion 
These results suggest that the shortening of T2 values should be taken into account when performing metabolite 
quantification. Also, the need of demonstrated similar results in in-vivo studies, since the presence of iron deposits or 
other factors affecting the water T2 decay measurements could explain part of the inter-subject variability in the 
metabolite concentration and ratio quantification. 
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Introduction 
Iron is known to accumulate in the brain as a function of age.[1, 2] However, this process is quite 
specific and involves the accumulation of iron-containing nuclei, which is one of the components of the 
basal ganglia. Concentrations of non-haemoglobin iron (mostly ferritin) increase in the putamen, motor 
cortex, prefrontal cortex, sensory cortex and thalamus during the first 30 to 35 years of life, and variable 
changes are observed in older individuals.[3] Different studies have shown that levels of H-ferritin in 
older individuals (67-88 years of age) were higher than in younger controls (27-66 years) in the frontal 
cortex, caudate nucleus, putamen, substantia nigra and globus pallidus. In the case of L-ferritin, this 
increase is observed only in the substantia nigra and globus pallidus.[4, 5] 
Iron is involved in the mechanisms that underlie many neurodegenerative diseases.[6-12] Conditions 
such as neuroferritinopathy and Friedreich ataxia are associated with mutations in genes that encode 
proteins that are involved in iron metabolism, and as the brain ages, iron accumulates in regions that are 
affected by Alzheimer's and Parkinson's disease. High concentrations of reactive iron can increase 
oxidative-induced neuronal vulnerability, and iron accumulation may increase the toxicity of 
environmental or endogenous toxins.[2] 
The iron effect on the magnetic resonance image (MRI) acquisition can be observed as a local hypo-
intensity.[2, 13, 14] The T2 effect of ferritin is much stronger than the T1 effect.[15] Prominently 
decreased signal intensity in the globus pallidum, reticular substantia nigra, red nucleus and dentate 
nucleus was routinely noted in 150 consecutive individuals on T2-weighted images (SE 2000/100) at field 
strength of 1.5 T.[16] This MR finding correlated closely with the decreasing estimated T2 relaxation 
times and the location of preferential accumulation of ferric iron using the Perls staining method on 
normal postmortem brains. The decreased signal intensity on T2-weighted images thus provides an in-
vivo map of the normal distribution of brain iron. Knowledge of the distribution of brain iron should assist 
in elucidating normal anatomic structures and in understanding neurodegenerative, demyelinating and 
cerebrovascular disorders.[7, 17] 
In proton magnetic resonance spectroscopy (
1
H-MRS), the main interest is to maximize the signal-to-
noise ratio of the spectrum peaks, avoiding signal loss due to T1 relaxation and T2 decay.[18] As 
mentioned before, the presence of iron deposits causes T2 shortening signal in T2-weighted images. 
However, no studies were found in the literature about this effect in the acquisition of the spectrum. This 
work studies the relationship between in-vitro 
1
H-MRS metabolite quantification and water T2 decay 
ratios. 
Materials and Methods 
In order to assess the in-vitro relationship between the water T2 relaxation times and the spectroscopic 
data, seven spherical phantoms (phantom1 to phantom7), each 40 mm in diameter, were filled with 
identical homogeneous aqueous solutions that mimic the metabolic properties of a healthy human brain. 
Magnetic nanoparticles with a Fe3O4 core, coated with dextran and 100 nm in diameter (Endorem, 
Guerbert, France), were used to dope phantoms with iron. Increasing concentrations of magnetic 
nanoparticles were added to an aqueous solution mimicking the metabolic properties of a healthy human 
brain. Final concentrations of magnetic nanoparticles in phantoms 1 to 7 were: 0; 0.5; 1.5; 2.5; 3.5; 5 and 
6 mgFe/ml, respectively. 
All MR images and spectroscopic data were acquired with a clinical GE Signa HDx 3.0T scanner 
using a single-channel quadrature head coil. The spectroscopy protocol consisted of a Point Resolved 
Spin Echo (PRESS) acquisition with TR = 1500 ms, TE = 35 ms and 128 signal averages per data frame 
with an eight-phase cycling scheme (2,048 data points per spectroscopy frame with a spectral band width 
of 2,500 Hz) resulting in an acquisition time of approximately 3.5 minutes. Suppression of unwanted 
water signal was accomplished by three chemical shift-selective (CHESS) radio frequency pulses. A 
single voxel (SV) with a nominal size of 12 × 12 × 12 mm was prescribed at the centre of the phantom. 
Phantoms were scanned one by one keeping the receiver gain constant from one phantom acquisition to 
the next. All spectroscopy data were subsequently processed off-line. 
Metabolite quantification was performed with the LCModel software.[19] This software fits 
experimental data with a so-called ‘basis set’ of spectra. The basis set is acquired from solutions acting as 
concentration references for the in-vivo acquisitions. This basis set has to be compatible with your data in 
terms of acquisition parameters such as field strength, localization sequence or TE. The LCModel 
software has a large collection of basis set for the most common acquisition protocols, like the one used 
for this work. The concentrations of the pertinent metabolites are determined in LCModel by scaling the 
relative areas and chemical shifts across the two sets of spectra. Fitting of the spectral peaks is thus 
achieved with a priori knowledge of their actual characteristics. The main brain metabolites choline 
(Cho), creatine (Cr), N-Acetyl aspartate (NAA), and myo-inositol (mI) were recorded. As metabolite 
concentrations are often presented as ratios, the ratios relative to Cr (NAA/Cr, Cho/Cr and mI/Cr) were 
also studied, whose level is explicitly assumed stable in normal as well as in many pathologic conditions. 
The water T2 imaging protocol consisted of a contiguous coronal T2-weighted Spin Echo (SE) pulse 
sequence using 3-mm slice thickness, with FOV = 22 × 22 cm, matrix size = 256 × 256, TR = 1500 ms 
and 11 echo times (TE = 20, 35, 40, 60, 70, 80, 105, 140, 144, 216 and 288 ms). Signal intensity (SI) was 
recorded from the same spatial localization prescribed during the SV acquisition. T2 maps were then 




Table 1 shows the water T2 relaxation times for each phantom together with their corresponding 
concentrations of iron nanoparticles and Figure 1 plots the water T2 relaxation times for each phantom. 
The T2 relaxation times are clearly seen to decrease as the concentration of iron increases. Line 
regression (dotted line) in Figure 1 confirms a strong correlation between water T2 and iron 
concentrations (or phantom number) with a Pearson's correlation coefficient [r] = −0.93. 
Table 1. Iron Nanoparticle Concentrations and Water T2 Relaxation Times in 
each Phantom 
 
Conc. (mgFe/ml) T2 (ms) 
   
phantom1 0 153 
phantom2 0.5 125 
phantom3 1.5 88 
phantom4 2.5 65 
phantom5 3.5 53 
phantom6 5 41 
phantom7 6 37 





Fig 1. Water T2 relaxation times of each phantom. 
Figure 2 demonstrates how reconstructed spectrum (bottom row) is affected by changes in the iron 
concentration. As the concentration increases, the overall amplitude of the corresponding spectra 




Figure 2. Water T2 maps (top row) and corresponding short echo time (TE = 35 ms) spectra (bottom row). All spectra shared the 
same amplitude scale. Single-voxel spectroscopy excitation borders (solid line) of nominal size 12 × 12 × 12 mm are shown overlaid 
onto T2 maps. 
In Figure 3A, a plot of absolute metabolite concentrations against decreasing water T2 values along 
the different phantoms is shown. Similarly, Figure 3B displays a plot of metabolite ratios versus 




Figure 3. Water T2 values for each phantom versus LCModel absolute metabolite concentrations (A) and ratios (B). 
The Pearson's correlation coefficient between the water T2 relaxation times and both the metabolite 
concentrations and ratios is shown in Table 2. The Pearson's correlation coefficient was on average [r] = 
0.97 and [r] = 0.85 for metabolite concentrations and ratios, respectively. 
Table 2. The Pearson's Correlation Coefficient [r] between Water T2 














The presence of iron nanoparticles causes a signal drop in the computed water T2 maps (Fig 2, top 
row), which is also accompanied by noticeable changes in the reconstructed LCModel spectra (Fig 2, 
bottom row). The latter causes underestimation in the absolute metabolite quantification. This effect is 
also demonstrated in the observed correlation between the water T2 relaxation times and both the 
metabolite concentrations and ratios (Fig 3). 
Magnetic resonance spectroscopy is a valuable diagnostic tool, which, in combination with MRI, 
enhances tissue characterization of intracranial lesions. Current clinical practice includes the use of 
metabolite ratios to aid tumor diagnosis and staging. Also, 
1
H-MRS is used in clinical practice to 
identifying evolutionary patterns of regional metabolite abnormalities in neurodegenerative diseases such 
as Alzheimer's disease and neurological disorders such as Parkinson disease, both of them affected by 
iron accumulation in the brain. As indicated in Figure 3, the presence of iron deposits could be one of the 
reasons affecting the accuracy of current spectroscopy diagnosis. 
These results suggest that the shortening of T2 values should be taken into account when performing 
metabolite measurements. Similar results are still to be demonstrated in-vivo, since the presence of iron 
deposits or other factors affecting the water T2 decay measurements, such as microcalcifications and 
microbleeds, could explain part of the inter-subject variability in the metabolite concentration and ratio 
quantification. 
These findings show that the T2 values should be considered in clinical practice when performing 
1
H-
MRS in pathologies affected by iron accumulation. Not doing so could lead to an underestimation of the 
metabolite quantification due to the shortening of T2 values, mainly in those metabolites with short T2 
water relaxation times only visible with short TE 
1
H-MRS, such as mI. As shown in Figure 3B, ratios are 
much less affected to T2 variations, so relative quantification should be routinely used in clinical 
applications affected by iron accumulation, since correlated effects which influence all metabolite signals 
to the same degree are potentially corrected by forming ratios. When absolute quantification is required, 
the imaging protocol should included a iron-sensitive T2-weighted imaging, like SE pulse sequence with 
multiples echo's or Gradient Echo for T2* relaxation times. The LCModel's absolute concentration for 
each peak in the spectrum should be proportionally weighted by the T2 values within the spectroscopic 
voxel. A reference spectrum is usually acquired from the contralateral region of the patient's brain in focal 
pathologic conditions, such as tumors, to calculate normalized ratios using the metabolic values from the 
contralateral normal side. This approach could be also applied for the iron-normalization of metabolite 
concentrations by using brain regions with no preferential iron accumulation as reference for 
normalization. 
The effect of water T2 shortening in 
1
H-MRS quantification could become more important when 
performing group comparisons in clinical studies involving 
1
H-MRS in elder patients or in pathologies 
with evident signs of iron accumulation, microcalcifications or microbleeds, since each subject may be 
affected by the T2 shortening in different degrees. In this case, it should be necessary to introduce the 
measurement of water T2 relaxation times as a new confounding variable in the statistical analysis. 
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